Tag: RayzeBio
-
How to Trade the Biotech M&A Boom
Biotech stocks are breaking higher. All thanks to the return of M&A. Most recently, Bristol Myers agreed to acquire RayzeBio in a $4.1 billion deal, which is a 100% premium to its Friday closing price. “This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth…